CompumedicsASX:CMP +2.00%61 PS Ratio is 0.86 as of Jun. 24, 2026, which is 51% below its 10-year median of 1.77. GuruFocus rates ASX:CMP with a GF Score™ of 61/100 and a GF Value™ of A$0.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Compumedics ranks better than 84.45% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Compumedics's share price is A$0.255.
Compumedics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.30. Hence, Compumedics's PS Ratio for today is 0.86.
The historical rank and industry rank for Compumedics's PS Ratio or its related term are showing as below:
ASX:CMP'
s PS Ratio Range Over the Past 10 Years
Min: 0.25 Med: 1.77 Max: 4.01
Current: 0.86
During the past 13 years, Compumedics's highest PS Ratio was 4.01. The lowest was 0.25. And the median was 1.77.
ASX:CMP's PS Ratio is ranked better than 84.45% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.855
vs ASX:CMP: 0.86
During the past 12 months, the average Revenue per Share Growth Rate of Compumedics was 15.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 19.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.60% per year.
During the past 13 years, Compumedics's highest 3-Year average Revenue per Share Growth Rate was 66.70% per year. The lowest was -12.40% per year. And the median was 0.90% per year.
Back to Basics: PS Ratio
Compumedics (ASX:CMP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Compumedics PS Ratio Related Terms
Compumedics PS Ratio Historical Data
* Premium members only.
The historical data trend for Compumedics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Compumedics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Compumedics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Compumedics's Share Price of today is A$0.255.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Compumedics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Compumedics (ASX:CMP) has a PS Ratio of 0.86 as of Jun. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Compumedics and its competitors. This is 51% below median its historical median of 1.77. Over the past decade, Compumedics' PS Ratio has ranged from 0.25 to 4.01. According to the industry distribution chart, Compumedics ranks #125 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 15.5%.
Is Compumedics' PS Ratio too high?
Compumedics' current PS Ratio of 0.86 is 51% below median its 10-year median of 1.77. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 4.01. The Medical Devices & Instruments industry median PS Ratio is 2.86. Compumedics' value of 0.86 is 69.9% below this industry median. Based on the distribution chart, Compumedics ranks #125 out of 804 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Compumedics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #125 out of 804 companies for PS Ratio. This places Compumedics in the top 16% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.86. Compumedics' value of 0.86 is 69.9% below this benchmark. Historically, Compumedics' own PS Ratio has ranged from 0.25 to 4.01 over the past decade. While the company's 10-year median is 1.77 vs. the industry median of 2.86, Compumedics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current PS Ratio of 0.86 is 69.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current PS Ratio is 0.86, which is 51% below median its own 10-year median of 1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.31, compared to a current price of A$0.26 — trading 17.7% below its estimated fair value. The current PS Ratio is 0.86, which is 51% below median its 10-year median of 1.77 and 69.9% below the Medical Devices & Instruments industry median of 2.86. Compumedics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current PS Ratio is 0.86 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.26 is trading 17.7% below its estimated GF Value™ of A$0.31.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
PS Ratio: 0.86 (51% below median its 10-year median of 1.77)
GF Value™: A$0.31 vs. price of A$0.26 (17.7% below fair value)
Industry Position: 69.9% below the Medical Devices & Instruments median (#125 of 804)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
61GF Score
Get the complete analysis for ASX:CMP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
